– Interview with Marleen Zuk, Ph.D., Professor of Biology at the University of California-Riverside

Previous articleAdvanced Cancer Therapeutics Gains License from Brown Cancer Center
Next articleProximagen to Secure About $80M to Finance Purchase and Licensing of Drug Assets